175 related articles for article (PubMed ID: 26982343)
1. Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.
Tayao M; Andrici J; Farzin M; Clarkson A; Sioson L; Watson N; Chua TC; Sztynda T; Samra JS; Gill AJ
PLoS One; 2016; 11(3):e0150338. PubMed ID: 26982343
[TBL] [Abstract][Full Text] [Related]
2. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
3. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.
Andrici J; Parkhill TR; Jung J; Wardell KL; Verdonk B; Singh A; Sioson L; Clarkson A; Watson N; Sheen A; Farzin M; Toon CW; Gill AJ
Pathology; 2016 Jun; 48(4):336-40. PubMed ID: 27114369
[TBL] [Abstract][Full Text] [Related]
5. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
[TBL] [Abstract][Full Text] [Related]
7. BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice.
Perkail S; Andricovich J; Kai Y; Tzatsos A
Nat Commun; 2020 Jun; 11(1):3018. PubMed ID: 32541668
[TBL] [Abstract][Full Text] [Related]
8. Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
Owen D; Sheffield BS; Ionescu D; Churg A
Hum Pathol; 2017 Feb; 60():82-85. PubMed ID: 27984124
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion.
Shen C; Wang Y; Wei P; Du X
BMC Cancer; 2016 Aug; 16(1):670. PubMed ID: 27553041
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of annexin 1 in pancreatic cancer and its clinical significance.
Bai XF; Ni XG; Zhao P; Liu SM; Wang HX; Guo B; Zhou LP; Liu F; Zhang JS; Wang K; Xie YQ; Shao YF; Zhao XH
World J Gastroenterol; 2004 May; 10(10):1466-70. PubMed ID: 15133855
[TBL] [Abstract][Full Text] [Related]
11. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma.
Yan S; He F; Luo R; Wu H; Huang M; Huang C; Li Y; Zhou Z
Tumour Biol; 2016 May; 37(5):6125-33. PubMed ID: 26611647
[TBL] [Abstract][Full Text] [Related]
13. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic-polypeptide in the human pancreas: expression and quantitative variation during development and in ductal adenocarcinoma.
Tamiolakis D; Simopoulos C; Kotini A; Venizelos I; Jivannakis T; Papadopoulos N
Acta Medica (Hradec Kralove); 2003; 46(1):9-14. PubMed ID: 12747533
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
19. Loss of BAP1 Leads to More YAPing in Pancreatic Cancer.
Brekken RA
Cancer Res; 2020 Apr; 80(8):1624-1625. PubMed ID: 32295782
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma.
Lee HJ; Pham T; Chang MT; Barnes D; Cai AG; Noubade R; Totpal K; Chen X; Tran C; Hagenbeek T; Wu X; Eastham-Anderson J; Tao J; Lee W; Bastian BC; Carbone M; Webster JD; Dey A
Cancer Res; 2020 Apr; 80(8):1656-1668. PubMed ID: 31988076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
